Yerly S - Search Results

1

Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: A large longitudinal cohort study.

Martischang R, Iten A, Arm I, Abbas M, Meyer B, Yerly S, Eckerle I, Pralong J, Sauser J, Suard JC, Kaiser L, Pittet D, Harbarth S. Martischang R, et al. Among authors: yerly s. Infect Control Hosp Epidemiol. 2022 Mar;43(3):326-333. doi: 10.1017/ice.2021.117. Epub 2021 Mar 19. Infect Control Hosp Epidemiol. 2022. PMID: 33736734 Free PMC article.

2

Response of HIV RNA to didanosine as a predictive marker of survival.

Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B, Perrin L. Yerly S, et al. AIDS. 1995 Feb;9(2):159-63. AIDS. 1995. PMID: 7718186

3

Foscarnet decreases human immunodeficiency virus RNA.

Kaiser L, Perrin L, Hirschel B, Furrer H, Von Overbeck J, Olmari M, Yerly S. Kaiser L, et al. Among authors: yerly s. J Infect Dis. 1995 Jul;172(1):225-7. doi: 10.1093/infdis/172.1.225. J Infect Dis. 1995. PMID: 7797916 Clinical Trial.

4

Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.

Yerly S, Kaiser L, Baumberger C, Hirschel B, Perrin LH. Yerly S, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):358-64. J Acquir Immune Defic Syndr Hum Retrovirol. 1995. PMID: 7882100

5

A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.

Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc D, Yerly S, Perrin LH, Hirschel B. Rutschmann OT, et al. Among authors: yerly s. AIDS. 1998 May 28;12(8):F71-7. doi: 10.1097/00002030-199808000-00003. AIDS. 1998. PMID: 9631134 Clinical Trial.

6

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.

Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S. Lorenzi P, et al. Among authors: yerly s. AIDS. 1999 Feb 4;13(2):F17-21. doi: 10.1097/00002030-199902040-00001. AIDS. 1999. PMID: 10202819

7

Transmission of antiretroviral-drug-resistant HIV-1 variants.

Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L. Yerly S, et al. Lancet. 1999 Aug 28;354(9180):729-33. doi: 10.1016/S0140-6736(98)12262-6. Lancet. 1999. PMID: 10475184

8

Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study.

Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, Furrer H, Hirschel B, Perrin L. Yerly S, et al. AIDS. 2000 Feb 18;14(3):243-9. doi: 10.1097/00002030-200002180-00006. AIDS. 2000. PMID: 10716500

9

Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.

Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher H, Bernasconi E, Perrin LH, Yerly S, Hirschel B. Rutschmann OT, et al. Among authors: yerly s. Antivir Ther. 1998;3 Suppl 4:65-7. Antivir Ther. 1998. PMID: 10723515 Clinical Trial.

10

A patient with HIV-1 superinfection.

Jost S, Bernard MC, Kaiser L, Yerly S, Hirschel B, Samri A, Autran B, Goh LE, Perrin L. Jost S, et al. Among authors: yerly s. N Engl J Med. 2002 Sep 5;347(10):731-6. doi: 10.1056/NEJMoa020263. N Engl J Med. 2002. PMID: 12213944 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

507 results

Search Page